Publications

Add filters (0)

898 results

Serum Markers of Fibroinflammatory Activity PRO-C3 and CPa9-HNE Are Associated with Liver-Related Outcomes in Patients with Chronic Hepatitis C.

May 15, 2026

J Infect Dis

Abstract BACKGROUND Chronic hepatitis C (CHC) infection remains a global health burden, contributing to the risk of long-term complications such as progressive fibrosis, cirrhosis, and hepatocellular carcinoma, particularly in undiagnosed or untreated individuals. Novel biomarkers for the assessment of disease progression and prognosis are required for fibroinflammatory chronic liver disease. Our study population from the […]

Read publication

Fibrosis progression rate and comparison of paired liver biopsy versus non-invasive tests as surrogate endpoints for clinical trials in MetALD and ALD.

May 13, 2026

Clin Gastroenterol Hepatol

Abstract BACKGROUND & AIMS Drug development for metabolic and alcohol-related liver disease (MetALD) and Alcohol-related liver disease (ALD) is emerging, but designing clinical trials remain challenging due to unknown disease progression rates and a lack of validated surrogate endpoints. We studied fibrosis progression rates and determinants of progression using dual liver biopsies and compared the […]

Read publication

Longitudinal Circulating Procollagen-markers PRO-C1 and PRO-C2 Reflect Pubertal Growth Spurt in Healthy Adolescents.

May 13, 2026

J Clin Endocrinol Metab

Abstract INTRODUCTION Epiphyseal growth plate development is stimulated by GH and IGF-I. Serum IGF-I is applied as an efficacy and safety marker, monitoring growth in short GH-treated children. However, IGF-I offers poor guidance to clinicians, especially in children without GHD. Thus, novel biomarkers reflecting endogenous and GH-induced linear growth are needed. We evaluated the association […]

Read publication

Therapeutic subtypes of knee osteoarthritis: differential treatment effects among predicted endotypes in past clinical trials.

May 7, 2026

Arthritis Res Ther

Abstract BACKGROUND Molecular endotyping may facilitate the successful development of personalized treatments of knee osteoarthritis (KOA). The aim of this exploratory and hypothesis-generating study was to develop a clinically actionable tool for predicting molecular endotypes of KOA using blood-based biomarkers, and to explore the potential for differential treatment effects across biomarker-based endotypes in prior phase […]

Read publication

Increased remodeling of type XXII collagen is associated with an inflammatory phenotype in Crohn’s disease.

April 25, 2026

Sci Rep

Abstract In Crohn’s disease, extracellular matrix (ECM) dysfunction and loss of tissue integrity are key pathological features. Fibril-associated collagens with interrupted triple helices (FACIT) are known to regulate ECM assembly and mediate biophysical cues in their microenvironment but remain largely understudied. This study aimed to investigate a novel biomarker reflecting remodelling of the FACIT collagen […]

Read publication

Circulating Endotrophin Predicts Myocardial Fibrosis Burden and Is Sensitive to Antifibrotic Therapy.

April 17, 2026

JACC Adv

Abstract BACKGROUND Novel collagen-derived circulating peptides, such as endotrophin, have been proposed as biomarkers of myocardial fibrosis. OBJECTIVES We aimed to determine the effect of pirfenidone, an antifibrotic agent, on circulating levels of these peptides, and their association with cardiovascular magnetic resonance extracellular volume (ECV). METHODS In the PIROUETTE (Pirfenidone in Patients with Heart Failure […]

Read publication

Prognostic Performance of Phosphatidylethanol With Noninvasive Liver Fibrosis Tests in Alcohol-Related Liver Disease.

April 1, 2026

Gastroenterology

Abstract BACKGROUND & AIMS Alcohol is a key driver of liver-related mortality, and phosphatidylethanol (PEth) is a direct biomarker of alcohol intake. We investigated the prognostic performance of PEth with noninvasive liver fibrosis tests (NITs) for predicting hepatic decompensation in an alcohol-related liver disease (ALD) at-risk population. METHODS Prospective cohort study with 411 at risk […]

Read publication

A Novel Fibroblast Activation Protein-Based Algorithm to Assess Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.

April 1, 2026

J Gastroenterol Hepatol

Abstract BACKGROUND Noninvasive fibrosis testing is crucial for metabolic dysfunction-associated steatotic liver disease (MASLD) management. This study evaluated a marker of activated mesenchymal fibrogenic cells, circulating fibroblast activation protein (cFAP), in a novel diagnostic algorithm, FAP Index, for patients with MASLD. METHODS Two retrospective cohorts recruited from tertiary hepatology clinics were studied as training (n = 160) […]

Read publication